Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.52 ($15K) on 2015-10-05, disclosed to the SEC on 2015-10-07.
Scheduled sale ($15k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.52 | 1,400 | $2K | 14.0% |
| 2 | $1.52 | 6,916 | $11K | 69.1% |
| 3 | $1.53 | 584 | $894 | 5.9% |
| 4 | $1.53 | 1,100 | $2K | 11.1% |
| Total | $1.52 avg | 10,000 | $15K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |